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We evaluated two methods from Roche and Promega for RNA extraction prior to the genotypic detection of
human immunodeficiency virus type 1 resistance by line probe assay (LiPA). Fifty plasma RNA extracts were
processed in parallel by LiPA. Results obtained by the Roche method were superior in the proportion of
amplified samples, the percentage of mutated samples, and band intensity.
From February to May 2001, 50 plasma samples from dif-
ferent patients were randomly selected from viral load (VL)
determination requests that had 1,000 RNA copies/ml.
All samples were processed for VL analysis by means of
PCR after previous retrotranscription (reverse transcriptase
[RT]-PCR) (Cobas Amplicor HIV-1 Monitor; Roche Diagnos-
tics, Branchburg, N.J.) in its ultrasensitive version with a
threshold of 50 RNA copies/ml. This version includes ultra-
centrifugation at 23,600  g of 500 l of each plasma sample
at 2 to 8°C for 60 min prior to the viral particle lysis. RNA is
extracted by adding a chaotropic agent (guanidinium-thiocya-
nate) followed by RNA precipitation with ethanol. After VL
determination all RNA extracts were preserved at 80°C.
RNA from samples with a VL of1,000 RNA copies/ml was
also extracted by using the SV Total RNA Isolation System
(Promega Corporation, Madison, Wis.). This method is based
on a lysis-centrifugation process followed by a column filtration
through a silica membrane in an RNase-free environment
starting with 125 l of plasma.
RNA extracts obtained by the two methods were tested in
parallel for the detection of genotypic resistance by means of
the commercial line probe assay (LiPA) (INNO-LiPA HIV-1
RT and INNO-LiPA HIV-1 Protease; Innogenetics, Ghent,
Belgium).
Briefly, LiPA is based on a post-RT-PCR hybridization that
takes place on nitrocellulose strips onto which specific oligo-
nucleotide probes are fixed in parallel lines. RT-PCR was
carried out following the manufacturer’s instructions by using
the RT-PCR Access kit (Promega Corporation), except that
the primers used were those included in the LiPA Amplifica-
tion kit. This assay allows the study of wild-type and mutant
sequences at codons 41, 69, 70, 74, 184, and 215 of the RT gene
(LiPA RT) and at codons 30, 46, 48, 50, 54, 82, 84, and 90 of
the protease (P) gene (LiPA P). Mutations in these positions
have been reported as associated with resistance to nucleoside
RT inhibitors and to protease inhibitors. cDNA synthesis and
PCR with biotinylated primers were performed as described by
Stuyver et al. (13). Hybridization was performed according to
the manufacturer’s instructions. Briefly, biotinylated DNA was
hybridized with specific oligonucleotide probes immobilized in
parallel lines on membrane-based strips. After hybridization,
streptavidin labeled with alkaline phosphatase was added and
bound to biotinylated hybrids. Incubation with a chromogen
resulted in a purple-brown precipitate visible to the naked eye.
Comparative reading of strip bands was done subjectively.
Extraction by Promega was taken as reference. We adopted a
triple strategy. First, the human immunodeficiency virus (HIV)
control band intensity was checked. Second, the intensities of
the rest of the bands were checked, and finally, the appearance
of different bands by each extraction method was evaluated.
Our findings were classified into four groups: (i) equal inten-
sity, when all bands were similar; (ii) intensity 1, when the
HIV control band was slightly darker by the Roche method
with the same number of bands; (iii) intensity 2, when the
HIV control band and the rest of the bands were markedly
darker, with the same number of bands, or an extra band was
observed by the Roche method; (iv) intensity 3, when band
coloring was markedly superior by the Roche method and
more than one extra band appeared. When the Roche extrac-
tion strip showed lower intensity than the Promega strip, a
similar assessment was done using negative figures.
Interpretation of the mutations found was done following
the manufacturer’s instructions and according to the Medscape
Guide to Antiretroviral Resistance Mutations (http://hiv
.medscape.com/updates/quickguide) and to the International
AIDS Society-USA Panel (6).
A descriptive study of all findings was carried out using the
statistical program SPSS 9.0 for Windows. “Ji-square” tests
were applied to study the possible relations between the dif-
ferent variables studied.
PCR amplification results of the extracts obtained by each
method were different for LiPA RT and for LiPA P, the dif-
ferences being statistically significant in both cases (P 0.001).
For LiPA RT a successful amplification was achieved after
Promega extraction in 33 of 50 samples (66.0%; the 95% con-
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fidence interval [CI] was 51.2 to 78.8) and in 49 of 50 samples
after Roche extraction (98%; 95% CI, 89.3 to 99.9). For LiPA
P a successful amplification was obtained in 38 of 50 Promega
extracts (76.0%; 95% CI, 61.8 to 86.9) and in 100.0% of Roche
extracts (95% CI, 92.8 to 100.0).
Comparative analysis of the results obtained by the two
extraction methods led to discrepancies in findings at three
different levels. First, in three samples the final LiPA interpre-
tation was “wild type” for the Promega extract but “mutant”
for the corresponding Roche extract. This happened in two
LiPA RT determinations and in one LiPA P determination.
Second, 13 samples that did not amplify after Promega extrac-
tion were interpreted as “mutant” after successful amplifica-
tion of the corresponding Roche extracts. This happened in
four samples for both LiPA RT and LiPA P, in seven samples
for LiPA RT alone, and in two samples only for LiPA P. Of the
16 samples included in the previous two levels, 10 (62.5%) had
VL levels of 50,000 RNA copies/ml, but no statistical signif-
icance was observed. Third, from the group of samples suc-
cessfully amplified and in which resistance mutations were
present after extraction by both methodologies, disagreements
could be documented both in the absolute frequency of ap-
pearance of individual mutations and in the patterns of com-
bined mutations observed. Tables 1 and 2 present the disagree-
ments observed for both LiPA RT and LiPA P, taking into
account the outcome of the RNA extraction method; findings
related to absolute mutation frequency (column subtotals) and
to different combined mutation patterns (totals by rows) are
shown. A tick () marks which individual and combined mu-
tations were present in each RNA extraction method; this is
considered in the percentage calculation, which is shown in
parentheses.
When differences in the band coloring intensity observed
were analyzed for each sample according to the extraction
method, for LiPA RT 11 samples (33.3%; 95% CI, 17.9 to
51.8) had the same intensity. In 21 cases Roche band intensity
was superior, being classified as intensity 1 in 11 cases
(33.3%; 95% CI, 17.9 to 51.8), as intensity 2 in 4 cases
(12.1%; 95% CI, 3.4 to 28.2), and as intensity 3 in 6 samples
(18.2%; 95% CI, 6.9 to 35.4). Only once was the Roche band
intensity lower than that of Promega (intensity 1). For LiPA
P, in 31 samples (81.6%; 95% CI, 65.7 to 92.2) the band
intensities for the two extraction methods were equal. In six
samples intensity was superior, the distribution being as fol-
TABLE 1. Discrepancies in results observed for LiPA RT according to the RNA extraction method in the absolute frequency of
each mutation (column subtotals) and in combined mutation patterns (total by rows)
Presence of mutation and absolute frequency (%) by Roche (next-to-last row)
and by Promega (last row)
Pattern
frequency (%)
L41(T) L41(C) R70 D69 D69R70 N69R70 V74 V184 Y215(18) Y215(19) F215 Roche Promega
  1 (100)
     1 (100)
    1 (100)
    1 (100)
   1 (100)
   1 (100)
  1 (100)
  1 (100)
 1 (100)
   3 (100) 2 (66.7)
  1 (50) 2 (100)
 1 (100)
1 (100) 2 (66.7) 3 (50) 1 (100) 4 (100) 9 (90) 7 (70) 1 (100) 1 (50)
1 (33.3) 3 (50) 2 (50) 5 (50) 7 (70) 1 (50)
TABLE 2. Discrepancies in results observed for LiPA P according to the RNA extraction method in absolute frequency of
each mutation (column subtotals) and in combined mutation patterns (total by rows)
Presence of mutation and absolute frequency (%) by Roche (next-to-last row)
and by Promega (last row)
Pattern
frequency (%)
N30 I46 V48 V50 V54 A54 V84 F82 F82V84 A82 T82 T82V84 M90 Roche Promega
  1 (100)
  1 (100)
  3 (100) 2 (66.7)
 3 (100) 2 (66.7)
   1 (100)
  1 (100)
 3 (100) 2 (66.7)
  2 (100) 1 (50)
 1 (100)
6 (75) 1 (33.3) 1 (50) 3 (100) 2 (66.7) 6 (100)
6 (75) 2 (66.7) 1 (50) 2 (66.7) 2 (66.7) 3 (50)
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lows: five samples with intensity 1 (13.1%; 95% CI, 4.4 to
28.1) and one sample with intensity 2 (2.6%; 95% CI, 0.1 to
13.8). No samples with intensity 3 were found. In three cases
the result was classified as intensity 1 (7.9%; 95% CI, 1.6 to
21.3). A global comparison of the intensity differences between
the Roche and the Promega methods, grouping them as equal
or superior (for both LiPA techniques), shows statistical sig-
nificance (P  0.001).
The evidently differing results observed for the two extrac-
tion methods compared in this study highlight the importance
of this step. Extraction conditions the outcome of all PCRs (1,
2, 15, 17), which are likewise an indispensable prerequisite for
HIV genotypic resistance testing. In the literature that we have
reviewed, there are some references to extraction outcome
applied to HIV sequencing for genotypic resistance detection,
such as a comparison of Qiagen and Boom extractions carried
out by Niubó et al. (9) and the comparative study by Shafer et
al. (11) of the silica bead method versus extraction by phenol-
chloroform. Most published studies on the influence of RNA
extraction refer to the subsequent VL determination (4, 5, 14,
15, 17).
In our experience, the better results achieved by Roche
extraction could be explained by two reasons. First, it includes
an ultracentrifugation, an operation that improves the extrac-
tion yield due to the sample concentration provided (11, 17).
Second, the starting sample volume is greater (500 versus 125
l) (10, 14, 17). An additional advantage of this method is that
VL determination should be performed prior to HIV resis-
tance testing, and, as the Roche extraction method is used to
this effect, the extract obtained serves as starting material for
both techniques.
Our study is limited by the absence of an objective system for
band reading such as that provided by a densitometer, which
other authors say offers good outcome when applied to band
intensity recording (16). Assuming this limitation and having
defined reading criteria in order to compare the results ob-
tained by the two extraction methods, once again there is a
clear disagreement for LiPA RT, where band intensity was
equal for the two extraction methods in only one-third of the
samples.
The wide range of discrepant results observed in our study
again highlights the importance of the extraction step. This fact
is especially significant because of the relevant information
brought to the clinician for therapeutic patient management,
particularly for those patients who have already experienced
any therapeutic failure (7, 8, 12). The little importance given to
this technical aspect is somewhat surprising in such a widely
studied matter as HIV resistance testing is in other aspects. We
therefore consider that studies such as the present comparing
more extraction methods are needed to optimize the outcome
of genotypic HIV resistance testing techniques.
The work carried out by our group faithfully reflects tech-
nical problems within the virology laboratory setting. However,
we do not ignore that the critical point, as recommended by
some authors (3, 6; see also http://www.msc.es/sida/asistencia
/resistencias.htm), is the transcription or translation of such
information to the clinical follow-up of each patient. This is the
only way that the technical effort of those devoted to labora-
tory diagnosis can be efficiently applied in the optimization of
therapeutic resources.
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